A share price of Regeneron Pharmaceuticals, Inc [REGN] is currently trading at $587.85, up 0.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REGN shares have gain 5.37% over the last week, with a monthly amount drifted -11.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners upgraded its rating to Outperform on February 05, 2025, and elevated its price target to $834. On January 16, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $738 on the stock. Wolfe Research initiated its recommendation with a Outperform and recommended $1150 as its price target on November 15, 2024. Citigroup started tracking with a Neutral rating for this stock on November 14, 2024, and assigned it a price target of $895. In a note dated September 24, 2024, Leerink Partners downgraded an Market Perform rating on this stock and revised its target price from $1175 to $1077.
Regeneron Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $525.99 and $1211.20. Currently, Wall Street analysts expect the stock to reach $1037 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $587.85 at the most recent close of the market. An investor can expect a potential return of 76.41% based on the average REGN price forecast.
Analyzing the REGN fundamentals
Trailing Twelve Months sales for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] were 14.20B which represents 10.33% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 580.28 points at the first support level, and at 572.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 599.60, and for the 2nd resistance point, it is at 611.34.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] is 4.73. As well, the Quick Ratio is 3.95. Considering the valuation of this stock, the price to sales ratio is 4.48, the price to book ratio is 2.19 and price to earnings (TTM) ratio is 15.35.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
